Skip to main content
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: J Thorac Oncol. 2011 Sep;6(9):1521–1529. doi: 10.1097/JTO.0b013e3182289479

Figure 5.

Figure 5

Pharmacological inhibition of IKBKB in NSCLC cells. Alamar Blue cell viability assays were performed to measure the effect of IKBKB inhibition by a cell permeable, competitive ATP inhibitor, IKK-2 inhibitor IV on 5 NSCLC cell lines. H2122, H23, H3255, and HCC95 harboured genetic alterations to either IKBKB and/or one or more of the KEAP1 E3-ligase complex components while H1650 was not altered at the DNA level.